A history of a cGMP medical event investigation /

Beginning with the untimely death of a young mother, A History of a cGMP Medical Event Investigation unfolds a fictitious case study that captures how unchecked human flaws during the development and launch of a new drug can lead to disastrous consequences. Moreover, it illustrates how and why Six S...

Full description

Bibliographic Details
Main Author: Brown, Michael A., 1945-
Format: eBook
Language:English
Published: Hoboken, N.J. : John Wiley & Sons, [2013]
Subjects:
Online Access:Full Text via HEAL-Link
LEADER 07602nam a2200817 4500
001 ocn823645667
003 OCoLC
005 20170124070043.3
006 m o d
007 cr cnu---unuuu
008 130108s2013 nju ob 001 0 eng d
040 |a N$T  |b eng  |e pn  |c N$T  |d YDXCP  |d E7B  |d CDX  |d IDEBK  |d OCLCA  |d ORE  |d RECBK  |d OCLCO  |d DG1  |d UKDOC  |d OCLCF  |d CHVBK  |d OCLCA  |d EBLCP  |d DEBSZ  |d OCLCQ  |d DEBBG  |d GrThAP 
019 |a 823726452  |a 864914126 
020 |a 9781118494943  |q (electronic bk.) 
020 |a 1118494946  |q (electronic bk.) 
020 |a 9781118494936  |q (electronic bk.) 
020 |a 1118494938  |q (electronic bk.) 
020 |a 9781118494882  |q (electronic bk.) 
020 |a 1118494881  |q (electronic bk.) 
020 |z 9781118396612 
020 |z 1118396618 
028 0 1 |a EB00063750  |b Recorded Books 
029 1 |a CHBIS  |b 010259671 
029 1 |a CHVBK  |b 325941866 
029 1 |a DEBBG  |b BV041049284 
029 1 |a DEBBG  |b BV041070263 
029 1 |a DEBBG  |b BV041908800 
029 1 |a DEBSZ  |b 431281912 
029 1 |a NZ1  |b 15916132 
029 1 |a DEBBG  |b BV043395276 
035 |a (OCoLC)823645667  |z (OCoLC)823726452  |z (OCoLC)864914126 
043 |a n-us--- 
050 4 |a RM302.5  |b .B76 2013eb 
060 4 |a QV 26.5 
072 7 |a MED  |x 012000  |2 bisacsh 
082 0 4 |a 615.5/8  |2 23 
049 |a MAIN 
100 1 |a Brown, Michael A.,  |d 1945- 
245 1 2 |a A history of a cGMP medical event investigation /  |c Michael A. Brown. 
264 1 |a Hoboken, N.J. :  |b John Wiley & Sons,  |c [2013] 
264 4 |c ©2013 
300 |a 1 online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Beginning with the untimely death of a young mother, A History of a cGMP Medical Event Investigation unfolds a fictitious case study that captures how unchecked human flaws during the development and launch of a new drug can lead to disastrous consequences. Moreover, it illustrates how and why Six Sigma principles and methods should be applied to fully comply with FDA regulations at every stage of drug development and commercialization. From initial transgenic mouse studies to the FDA fatality investigation, this case study introduces all the key regulations and practices that govern the development, manufacture, and marketing of a new drug, including: [1] FDA Investigational and New Drug Application Processes, [2] FDA Code of Federal Regulations' current Good Manufacturing Practice (cGMP), [3] ISPE Good Automated Manufacturing Practice (GAMP) Readers will also be introduced to a variety of managers and researchers whose personal agendas conflict with best practices and therefore compromise the safety and effectiveness of a new drug product. Throughout the case study, the author offers tested and proven practices and tips so that these human flaws are not translated into drug product flaws. These practices and tips are critical and typically can only be learned through years of experience working in competitive drug development environments. A History of a cGMP Medical Event Investigation is ideal for students in biotechnology, pharmacology, engineering, and business management as well as professionals in biomedical and drug development. All readers will discover what can go wrong in developing and bringing a new drug to market. Most importantly, they will also learn how to apply Six Sigma principles and methods to ensure safe and effective product design, development, and manufacturing. 
504 |a Includes bibliographical references and index. 
588 0 |a Print version record. 
505 0 |a Title page; Copyright page; Dedication; Contents; Preface; ***; PART ONE: The Event; 1: Francesca; ***; PART TWO: Drug Discovery:Five Years Earlier; 2: Katlin BioScience: Transgenic Mouse Study; 3: Oxy-Fox Inhaler; 3.1 Kinnen Laboratories; 3.2 Kinnen Laboratories: Oxy-Fox Transfer; 3.3 Due-Diligence Team and Katlin Data Acceptance; PART THREE: Kinnen Oxy-Fox Inhaler Market Launch Program; 4: Agency IND and NDA Requirements, Six Sigma Charter, and Device Master Record; 4.1 Launch Team Meeting Number 1; ***; ***; ***; 4.2 Meeting with Medical Affairs: Toxicity Studies. 
505 8 |a 5: Meeting Minutes Guidelines5.1 Launch Team Meeting Number 2; ***; 6: Project Timing, Marketing Plan, and Offshore Molding; 6.1 Launch Team Meeting Number 3; 6.2 Project Financial Review; 6.3 Progress Meeting: Who Takes Credit for What?; 6.4 Morning meeting: Just-in-Time Manufacturing; 7: cGMP Process Validation Requirements; 7.1 Launch Team Meeting Number 4; ***; 8: Failure Mode Effects Analysis; 8.1 Launch Team Meeting Number 5; ***; 9: Design for Manufacturability, Design for Six Sigma, Concurrent Design; 9.1 Product Development Meeting Number 1; *** 
505 8 |a 9.2 Update Meeting with Ed Chase and Gordon Taylor10: Design Fishbone Diagram; 10.1 Launch Team Meeting Number 6; 11: Product Specifications; 11.1 Product Development Meeting Number 2; 12: Design Control; 12.1 Design Team Meeting Number 7; 12.2 Product Development Staff Meeting; 12.3 Engineering One-on-One; 12.4 Program Update; 13: Design of Experiments (DOE); 13.1 Molding Team Meeting; 14: Start-Up Issues; 14.1 Oxy-Fox Inhaler Wrap-Up and Equipment Start-Up; ***; 14.2 The Final Management Review; ***; PART FOUR: Present Day: Funeral; 15: Grief; ***; 16: The Autopsy Results; *** 
505 8 |a 17: The Agency***; ***; PART FIVE: Agency Medical Event Letter; 18: Kinnen Notification; 18.1 Another Agency Letter; 18.2 Medical Event Review Meeting; ***; 19: Investigation Team Management; 19.1. Morning Meeting with Gail Strom, Marcia Hines, and Dan Garvey; 20: DMAIC Investigation Process; 21: Internal Quality Review; 21.1 Meeting with Gail Strom and Marcia Hines; 21.2 Executive Management Review; ***; ***; ***; 22: The Agency Audit Letter; ***; 23: Agency Arrival; ***; 24: The Audit. 
505 8 |a 24.1 Agency Meeting to Review Qualification Documents and the Quality Acceptance Records of First Lot to Stock***; 24.2 Agency Meeting to Review the Oxy-Fox Inhaler Lot Used in the NDA Clinical Studies; 24.3 Agency Meeting to Review the Design and Program Team Meeting Minutes; ***; 24.4 Agency Meeting to Review the Due-Diligence Report, Katlin Studies, and Oxy-Fox Design History File; ***; 25: End-of-Day Agency Wrap-Up Meeting; ***; 26: Kinnen Management Review; ***; ***; PART SIX: Reckoning; 27: Blame and Responsibility; 27.1 The Investigation Is a Public Record; 27.2 Kinnen Wrap-Up; *** 
610 1 0 |a United States.  |b Food and Drug Administration. 
610 1 7 |a United States.  |b Food and Drug Administration.  |2 fast  |0 (OCoLC)fst00549734 
650 0 |a Drugs  |x Side effects. 
650 2 |a Adverse Drug Reaction Reporting Systems. 
650 2 |a Drug Therapy  |x adverse effects. 
650 2 |a Investigational New Drug Application. 
650 4 |a Adverse Drug Reaction Reporting Systems  |z United States. 
650 4 |a Drug Therapy  |x adverse effects  |z United States. 
650 4 |a Investigational New Drug Application  |z United States. 
650 4 |a United States. 
650 4 |a United States.  |x Food and drug administration. 
650 7 |a MEDICAL  |x Chemotherapy.  |2 bisacsh 
650 7 |a Drugs  |x Side effects.  |2 fast  |0 (OCoLC)fst00898912 
651 2 |a United States. 
655 4 |a Electronic books. 
776 0 8 |i Print version:  |a Brown, Michael A., 1945-  |t History of a cGMP medical event investigation.  |d Hoboken, N.J. : John Wiley & Sons, ©2013  |z 9781118396612  |w (DLC) 2012027158  |w (OCoLC)800720504 
856 4 0 |u https://doi.org/10.1002/9781118494943  |z Full Text via HEAL-Link 
994 |a 92  |b DG1